Drugs / Ledaborbactam etzadroxil

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06733675 Jan 2025 → Dec 2026 expected Basilea Pharmaceutica Recruiting No outcome recorded
Phase 1 NCT06665555 Nov 2024 → Mar 2025 Basilea Pharmaceutica Completed No outcome recorded
Phase 1 NCT05488678 Oct 2022 → Nov 2023 Basilea Pharmaceutica Completed No outcome recorded
Phase 1 NCT05527834 Sep 2022 → Feb 2023 Basilea Pharmaceutica Completed No outcome recorded
Phase 1 NCT04877379 Jun → Nov 2021 Basilea Pharmaceutica Completed No outcome recorded
Phase 1 NCT04243863 Jan 2020 → Apr 2021 Basilea Pharmaceutica Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Ledaborbactam etzadroxil Ledaborbactam etzadroxil (LED-E), a novel oral prodrug that converts to the active β-lactamase inhibitor (BLI) ledaborbactam (LED), is being developed in combination with...” PMID 40762486 Aug 2025
2

NCT06733675

NCT06665555

Known as LED-E “Ledaborbactam etzadroxil (LED-E), a novel oral prodrug that converts to the active β-lactamase inhibitor (BLI) ledaborbactam (LED), is being developed in combination with...” PMID 40762486 Aug 2025
1

“Ledaborbactam etzadroxil (LED-E) is an oral prodrug of ledaborbactam, a broad-spectrum β-lactamase inhibitor.” PMID 42008649 Apr 2026

Known as VNRX-5236 ETZADROXIL ChEMBL registry synonym — accepted as the source's own label CHEMBL4594425
Known as VNRX-7145 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05488678
1

NCT05527834

Action Inhibit “active β-lactamase inhibitor (BLI)” PMID 40762486 Aug 2025
Modality Small molecule CHEMBL4594425
Route Oral Oral dosing” NCT04243863